Overview

SentiAR has developed an augmented reality (AR) platform to enable 3D holographic visualization of a patient’s anatomy and doctor’s interventional instrument location. This provides the clinician with superior patient internal visibility, which should enable faster, more effective, and safer patient care where location precision is essential, and instrumentation is the physician’s primary source of information and navigation. The initial application of the technology is for more accurate catheter ablation procedures to treat cardiac arrhythmia. The platform is software-based, utilizes a hands-free, head-up display, and is built to scale beyond cardiology to revolutionize the way data and imaging results are displayed in the operating room. The technology was submitted for Class II FDA device approval in October 2019.

Team

sentiAR

Berk Tas

MBA, CEO

Berk has led the development of emerging technologies and companies in Fortune 500, private equity, venture capital-funded, and privately held organizations. Before joining SentiAR, he led the development of a novel Trans-aortic Valve Replacement technology into CE Mark studies at HLT Medical. In 2016, Berk played an integral role in the acquisition of Sensium, Oxford UK, a novel wireless monitoring technology. He holds an MBA from the Carlson School of Business at the University of Minnesota and a BS in Electrical Engineering and Physics from the School of Engineering at St Thomas University. Berk Tas resides in Minneapolis, Minnesota.

Read More Less
sentiAR

Jennifer Avari Silva

MD, FHRS, Co-Founder, CMO

Jennifer Avari Silva is responsible for the clinical application of SentiAR technology for patient use. She is an Assoc. Professor of Pediatrics at Washington University in St. Louis and Director of Pediatric Cardiac Electrophysiology at St. Louis Children’s Hospital, where she leads the largest pediatric electrophysiology program in the Midwest. Dr. Avari Silva has published numerous papers bringing new technologies to pediatric patients, allowing her to develop an extensive industrial network with companies that include St. Jude Medical, Medtronic, Biotronik, and Biosense Webster. Jennifer Silva is based in St. Louis, Missouri.

Read More Less
sentiAR

Jon Silva

Ph.D., FAHA, Co-Founder, CTO

Jon created the SentiAR visualization platform and has oversight for the overall technical design and development to meet current and future clinical applications. It was his original work that secured over $500K in grants to build the initial prototype on the Microsoft HoloLens platform for in-human engineering trials. As an Assoc. Professor of Biomedical Engineering at Washington University in St. Louis, his research laboratory specializes in applying computational approaches to address problems in cardiac electrophysiology. Jonathan is part of the Cardiac Bioelectricity and Arrhythmia Center, and his academic preparation includes a BS from Johns Hopkins University, an MS from Case Western Reserve University, and a Ph.D. in Biomedical Engineering, Washington University. Jon Silva is based in St. Louis, Missouri.

Read More Less
sentiAR

Michael Southworth

MS-EE, Co-Founder, VP Technology

Michael is responsible for the company’s holographic platform validation, software planning, and team execution. Before joining the project, he developed 3D computer vision exploitation of sensor data for use in airborne platforms as an Electrophysics scientist at Boeing Research and Technology. From 2007-2015 at the Johns Hopkins University Applied Physics Laboratory (JHUAPL), Michael specialized in the rapid development of embedded systems for direct deployment to the Department of Defense end-users, primarily focused on the technical integration of wireless embedded systems with emerging microelectromechanical systems (MEMS) sensor technology, navigation, electro-optical sensor development and 3D sensor exploitation. Michael earned his BS from UC Berkeley and a dual MS from Johns Hopkins University. Michael Southworth is based in St. Louis, Missouri.

Read More Less

Investor Presentation

Download Presentation

Our Take

SentiAR, Inc. (“the Company” or “SentiAR”) has developed an augmented reality (AR) platform to enable 3D holographic visualization of a patient’s anatomy and doctor’s interventional instrument location. This provides the clinician with superior patient internal visibility, which should enable faster, more effective, and safer patient care where location precision is essential, and instrumentation is the physician’s primary source of information and navigation. The initial application of the technology is for more accurate catheter ablation procedures to treat cardiac arrhythmia. The platform is software-based, utilizes a hands-free, head-up display, and is built to scale beyond cardiology to revolutionize the way data and imaging results are displayed in the operating room. The technology was submitted for Class II FDA device approval in October 2019.

Read our full research report: SentiAR Our Take 2019

News and Press

Sardar et al. Artificial Intelligence and Interventional Cardiology. JACC

CARDIOVASCULAR INTERVENTIONS VOL. 12; NO.14, JULY 2019, 1293 – 303

Documents

VCapital SentiAR Subscription Agreement

Subscription Documents to make an investment in VCapital SentiAR, LLC

VCapital SentiAR Offering Memorandum

Offering Memorandum of VCapital SentiAR, LLC

VCapital SentiAR LLC Agreement

Limited Liability Company Agreement of VCapital SentiAR, LLC